Skip to main content

Advertisement

Table 1 Relationship between clinical parameters and IFI44L expression in hepatocellular patients

From: IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway

   IFI44L  
Variables N Low High p-value
Age (years)
  < 65 100 49 (49%) 51 (51%) 0.892
65 117 56 (48%) 61 (52%)  
Gender
 Female 58 35 (60%) 23 (40%) 0.306
 Male 159 75 (47%) 84 (53%)  
Differentiation
 Well 12 3 (25%) 9 (75%) 0.892
 Moderate 105 55 (52%) 50 (48%)  
 Poor 94 47 (50%) 47 (50%)  
 Undifferentiation 6 1 (17%) 5 (83%)  
Stage
 I, II 180 84 (47%) 96 (53%) 0.029
 III, IV 37 25 (68%) 12 (32%)  
Hepatitis B surface antigen
 Negative 106 52 (49%) 54 (51%) 0.892
 Positive 111 56 (51%) 55 (49%)  
Hepatits C virus
 Negative 150 74 (49%) 76 (51%) 0.883
 Positive 67 34 (51%) 33 (49%)  
Tumor Number
 Single 177 87 (49%) 90 (51%) 0.841
 Multiple 40 21 (53%) 19 (47%)  
Tumor size
  < 5 cm 140 59 (42%) 81 (58%) 0.002
5 cm 77 49 (64%) 28 (36%)  
Relapse
 - 196 91 (46%) 105 (54%) 0.002
 + 21 17 (81%) 4 (19%)